User login
Photo by Esther Dyson
A new study suggests that, in recent years, there has been a decrease in clinical trials funded by the National Institutes of Health (NIH) but an increase in trials with funding from other sources.
Researchers looked at trials newly registered on ClinicalTrials.gov and observed a substantial increase in trial listings from 2006 through 2014.
During that time period, the number of NIH-funded trials declined, but the number of trials funded by other US federal agencies, industry, and other groups (such as universities and organizations) increased.
Stephan Ehrhardt, MD, of Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, and his colleagues conducted this study and recounted their findings in a letter to JAMA.
The researchers downloaded data from ClinicalTrials.gov, searched for “interventional study” and obtained counts of newly registered trials by funder type: “NIH,” “industry,” “other US federal agency,” or “all others (individuals, universities, organizations).”
According to the “first received” date (when trials were first registered with ClinicalTrials.gov), the number of newly registered trials increased from 9321 in 2006 to 18,400 in 2014 (97.4%).
During the same period, the number of industry-funded trials increased from 4585 to 6550 (42.9%), and the number of NIH-funded trials decreased from 1376 to 1048 (23.8%).
The number of trials funded by other US federal agencies increased from 263 to 339 (28.9%), and the number of trials funded by “all others” increased from 3240 to 10,597 (227.1%).
The researchers also examined the data according to the trial start date and observed similar patterns. They found the total number of trials increased from 9208 in 2006 to 14,618 in 2014 (58.8%).
The number of industry-funded trials increased from 4516 to 5274 (36.1%), and the number of NIH-funded trials decreased from 1189 to 873 (26.6%).
The number of trials funded by other US federal agencies increased from 229 to 292 (27.5%), and the number of trials funded by “all others” increased from 3397 to 8295 (144.2%).
Dr Ehrhardt said he believes the decline in NIH-funded studies can be traced to 2 things: flat NIH funding (the 2014 budget was 14% less than in 2006, after adjusting for inflation) and greater competition for these limited dollars from other, relatively new research areas such as genomic research or personalized medicine studies. 
Photo by Esther Dyson
A new study suggests that, in recent years, there has been a decrease in clinical trials funded by the National Institutes of Health (NIH) but an increase in trials with funding from other sources.
Researchers looked at trials newly registered on ClinicalTrials.gov and observed a substantial increase in trial listings from 2006 through 2014.
During that time period, the number of NIH-funded trials declined, but the number of trials funded by other US federal agencies, industry, and other groups (such as universities and organizations) increased.
Stephan Ehrhardt, MD, of Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, and his colleagues conducted this study and recounted their findings in a letter to JAMA.
The researchers downloaded data from ClinicalTrials.gov, searched for “interventional study” and obtained counts of newly registered trials by funder type: “NIH,” “industry,” “other US federal agency,” or “all others (individuals, universities, organizations).”
According to the “first received” date (when trials were first registered with ClinicalTrials.gov), the number of newly registered trials increased from 9321 in 2006 to 18,400 in 2014 (97.4%).
During the same period, the number of industry-funded trials increased from 4585 to 6550 (42.9%), and the number of NIH-funded trials decreased from 1376 to 1048 (23.8%).
The number of trials funded by other US federal agencies increased from 263 to 339 (28.9%), and the number of trials funded by “all others” increased from 3240 to 10,597 (227.1%).
The researchers also examined the data according to the trial start date and observed similar patterns. They found the total number of trials increased from 9208 in 2006 to 14,618 in 2014 (58.8%).
The number of industry-funded trials increased from 4516 to 5274 (36.1%), and the number of NIH-funded trials decreased from 1189 to 873 (26.6%).
The number of trials funded by other US federal agencies increased from 229 to 292 (27.5%), and the number of trials funded by “all others” increased from 3397 to 8295 (144.2%).
Dr Ehrhardt said he believes the decline in NIH-funded studies can be traced to 2 things: flat NIH funding (the 2014 budget was 14% less than in 2006, after adjusting for inflation) and greater competition for these limited dollars from other, relatively new research areas such as genomic research or personalized medicine studies.
Photo by Esther Dyson
A new study suggests that, in recent years, there has been a decrease in clinical trials funded by the National Institutes of Health (NIH) but an increase in trials with funding from other sources.
Researchers looked at trials newly registered on ClinicalTrials.gov and observed a substantial increase in trial listings from 2006 through 2014.
During that time period, the number of NIH-funded trials declined, but the number of trials funded by other US federal agencies, industry, and other groups (such as universities and organizations) increased.
Stephan Ehrhardt, MD, of Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, and his colleagues conducted this study and recounted their findings in a letter to JAMA.
The researchers downloaded data from ClinicalTrials.gov, searched for “interventional study” and obtained counts of newly registered trials by funder type: “NIH,” “industry,” “other US federal agency,” or “all others (individuals, universities, organizations).”
According to the “first received” date (when trials were first registered with ClinicalTrials.gov), the number of newly registered trials increased from 9321 in 2006 to 18,400 in 2014 (97.4%).
During the same period, the number of industry-funded trials increased from 4585 to 6550 (42.9%), and the number of NIH-funded trials decreased from 1376 to 1048 (23.8%).
The number of trials funded by other US federal agencies increased from 263 to 339 (28.9%), and the number of trials funded by “all others” increased from 3240 to 10,597 (227.1%).
The researchers also examined the data according to the trial start date and observed similar patterns. They found the total number of trials increased from 9208 in 2006 to 14,618 in 2014 (58.8%).
The number of industry-funded trials increased from 4516 to 5274 (36.1%), and the number of NIH-funded trials decreased from 1189 to 873 (26.6%).
The number of trials funded by other US federal agencies increased from 229 to 292 (27.5%), and the number of trials funded by “all others” increased from 3397 to 8295 (144.2%).
Dr Ehrhardt said he believes the decline in NIH-funded studies can be traced to 2 things: flat NIH funding (the 2014 budget was 14% less than in 2006, after adjusting for inflation) and greater competition for these limited dollars from other, relatively new research areas such as genomic research or personalized medicine studies.